ASCO 2026
Presentations Supported by Bayer
May 29- June 2, 2026
Agenda of oral and poster presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Please see below to download a PDF for each presentation and view a video (where applicable). Access for each publication will be available after the congress presentation.
Please select a compound to navigate to all related publications.
DAROLUTAMIDE
Prostate-specific antigen outcomes of darolutamide and androgen deprivation therapy in patient subgroups by age, comorbidities, and concomitant medications: ARANOTE post hoc analyses
Date/Time: May 31, 2026 | 9:00 AM – 12:00 PM CDT
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Type: Poster Session
Presenting Author: Fred Saad
Abstract Number: 5103
Major adverse cardiovascular events in androgen receptor signaling inhibitor–treated patients with metastatic castration-sensitive prostate cancer
Date/Time: May 31, 2026 | 9:00 AM – 12:00 PM CDT
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Type: Poster Session
Presenting Author: Linden Huhmann
Abstract Number: 5107
Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology
Date/Time: May 30, 2026 | 4:24 PM – 4:36 PM CDT
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Type: Oral Abstract Session
Presenting Author: Alicia K. Morgans
Abstract Number: 5005
A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy–naïve recurrent and/or metastatic androgen receptor (AR)–positive salivary gland cancer (ETCTN 10553)
Date/Time: June 1, 2026 | 8:48 AM – 9:00 AM CDT
Session: Head and Neck Cancer
Type: Clinical Science Symposium
Presenting Author: Alan Loh Ho
Abstract Number: 6012
Comeback from long-course ADT with relugolix (rel) and darolutamide (daro) in hormone-sensitive prostate cancer (PC) (CLEARED)
Date/Time: May 31, 2026 | 9:00 AM – 12:00 PM CDT
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Type: Poster Session
Presenting Author: Atish Choudhury
Abstract Number: 5083
Classification tree phenotypes for early treatment-limiting toxicity after androgen receptor pathway inhibitor initiation in metastatic hormone-sensitive prostate cancer from the IRONMAN registry
Date/Time: May 31, 2026 | 9:00 AM – 12:00 PM CDT
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Type: Poster Session
Presenting Author: Alexandra Larkin
Abstract Number: 5095
Real-world cost effectiveness of androgen receptor pathway inhibitors for metastatic hormone sensitive prostate cancer: An economic evaluation utilizing data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN)
Date/Time: June 1, 2026 | 9:00 AM – 12:00 PM CDT
Session: Quality Care/Health Services Research
Type: Poster Session
Presenting Author: Rebecca Green
Abstract Number: 11164
LAROTRECTINIB
Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: An updated analysis
Date/Time: May 30, 2026 | 1:30 PM – 4:30 PM CDT
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Type: Poster Session
Presenting Author: Alexander E. Drilon
Abstract Number: 3145
Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis
Date/Time: May 31, 2026 | 9:00 AM – 12:00 PM CDT
Session: Lung Cancer—Non-Small Cell Metastatic
Type: Poster Session
Presenting Author: Jessica Lin
Abstract Number: 8618
Precision oncology in practice: Real-world multicenter experience with larotrectinib in pediatric extracranial NTRK fusion–positive tumors
Date/Time: June 1, 2026 | 1:30 PM - 4:30 PM CTD
Session: Pediatric Oncology
Type: Poster
Presenting Author: Rejin Kebudi
Abstract Number: 10036
RADIUM-223
ETCTN 10302: A randomized phase II trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer
Date/Time: May 30, 2026 | 1:30 PM – 4:30 PM CDT
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Type: Poster Session
Presenting Author: Jyoti Malhotra
Abstract Number: 3096
A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801)
Date/Time: May 29, 2026 | 2:45 PM – 2:57 PM CDT
Session: Genitourinary Cancer—Kidney and Bladder
Type: Oral Abstract Session
Presenting Author: Rana R. McKay
Abstract Number: 4500
Cell-free DNA nucleosome and genomic signatures as predictors of outcomes with radium-223 in metastatic castration-resistant prostate cancer
Date/Time: May 31, 2026 | 9:00 AM – 12:00 PM CDT
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Type: Poster Session
Presenting Author: David Chen
Abstract Number: 5039
Quality of life analysis from a multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 versus radium-223 in metastatic castration-resistant prostate cancer with bone metastases (COMRADE)
Date/Time: May 31, 2026 | 9:00 AM – 12:00 PM CDT
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Type: Poster Session
Presenting Author: Rana R. McKay
Abstract Number: 5040
REGORAFENIB
Evaluation of the combination of regorafenib + avelumab in patients with HPV-associated cancer: The phase II REGOMUNE study
Date/Time: May 30, 2026 | 8:42 AM – 8:48 AM CDT
Session: Developmental Therapeutics—Immunotherapy
Type: Rapid Oral Abstract Session
Presenting Author: Sophie Cousin
Abstract Number: 2517
SEVABERTINIB
SOHO-01: Updated safety and efficacy of sevabertinib in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC)
Date/Time: May 31, 2026 | 9:00 AM – 12:00 PM CDT
Session: Lung Cancer—Non-Small Cell Metastatic
Type: Poster Session
Presenting Author: Herbert H. Loong
Abstract Number: 8862
The compendium provided by Bayer is a compilation of Bayer sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from The American Society of Clinical Oncology (ASCO) and from the authors. The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Reused with permission. © 2026 The American Society of Clinical Oncology (ASCO). All rights reserved.
For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR
© 2026 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981 USA. 5/26
MA-M_DAR-US-0402-1
MA-M_DAR-US-0403-1